Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Complementary and Alternative Medicine

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Treatment of allergic rhinitis with acupoint herbal plaster: an oligonucleotide chip analysis

  • Horng-Sheng Shiue1,
  • Yun-Shien Lee2,
  • Chi-Neu Tsai1 and
  • Hen-Hong Chang3, 4Email author
BMC Complementary and Alternative MedicineBMC series – open, inclusive and trusted201616:436

https://doi.org/10.1186/s12906-016-1418-0

Received: 8 March 2016

Accepted: 19 October 2016

Published: 4 November 2016

Abstract

Background

Allergic rhinitis is regarded as an imbalanced Th1/Th2 cell-mediated response. The present study used microarray analysis to compare gene expression levels between allergic rhinitis patients before and after a series of acupoint herbal plaster applications.

Methods

In this experimental pilot study, volunteers experiencing sneezing, runny nose, and congestion for more than 9 months in the year following initial diagnoses were included after diagnostic confirmation by otolaryngologists to exclude patients with sinusitis and nasal polyps. Patients with persistent allergic rhinitis each received four acupoint herbal plaster treatments applied using the moxibustion technique. Clinical outcomes were evaluated using the Rhinitis Quality of Life Questionnaire (RQLQ). Peripheral blood samples were analyzed using an ImmunoCAP Phadiatop test, and patients were classified as phadiatop (Ph)-positive or -negative. Microarray results were analyzed for genes that were differentially expressed between (1) Ph-positive and -negative patients treated with herbal plaster; and (2) before and after herbal plaster treatment in the Ph-positive patient group. Unsupervised and supervised methods were used for gene-expression data analysis.

Results

Nineteen Ph-positive and four Ph-negative participants with persistent allergic rhinitis were included in the study. RQLQ results indicated that the 19 Ph-positive volunteers experienced improvement in six of seven categories following acupoint herbal plaster treatments, whereas the four Ph-negative participants reported improvement in only two categories. Hierarchical clustering and principle component analysis of the gene expression profiles of Ph-positive and –negative participants indicated the groups exhibited distinct physiological responses to acupoint herbal treatment. Evaluation of gene networks using MetaCore identified that the “Immune response_IL-13 signaling via JAK-STAT” and the “Inflammation_Interferon signaling” were down- and up-regulated, respectively, among Ph-positive subjects.

Conclusions

In this preliminary study, we find that the IL-13 immune response via JAK-STAT signaling and interferon inflammation signaling were down- and upregulated, respectively, in the Ph-positive group. Further studies are required to verify these pathways in Ph-positive patients, and to determine the mechanism of such pathway dysregulation.

Trial registration

ClinicalTrials.gov: NCT02486159. Registered 30 Jun 2015.

Keywords

Allergic rhinitisAcupoint herbal plasterOligonucleotide chip

Background

Many patients with allergic rhinitis have chosen complementary and alternative medicine (CAM), including traditional Chinese medicine (TCM) or acupuncture [1, 2], as they have found CAM to be more attractive and less invasive [1]. The World Health Organization (WHO) published an article examining CAM therapies for allergic rhinitis and asthma [2], which include major contributions from TCM and deserve our continued study to assess therapeutic efficacies and mechanisms. In addition to acupuncture and TCM to treat allergic rhinitis, acupoint herbal plaster applications have recently been used widely in Taiwan [35] and mainland China [6, 7] due to the noninvasive and easy to manipulate nature of these treatments. An herbal plaster is applied with a drug applicator using a technique akin to moxibustion, stimulating the skin at specific acupuncture points [3, 4]. Acupoint herbal plaster methods have been recommend for allergic rhinitis beginning in 2009 [8], and practitioners throughout Taiwan and China use similar approaches in the composition of herbal medicine, the herbal medicine application operating process [9] and what acupoints are used [10]. Clinical research regarding the application of acupoint therapy for allergic rhinitis has increased, and evidence-based methods have validated its efficacy and safety [7, 911]. However, the majority of these studies are clinical trials; therefore, the efficacy and mechanisms of acupoint herbal plaster treatment need to be validated via mechanistic, molecular methods [2, 9, 12].

We previously studied the effect of herbal plaster treatment for allergic rhinitis [13]. Ours was the first comprehensive clinical outcome assessment of acupoint herbal plaster therapy for allergic rhinitis using the Rhinoconjunctivitis and Rhinitis Quality of Life Questionnaire (RQLQ) [14]. We showed that acupoint herbal plaster for the treatment of allergic rhinitis is safe, effective, and associated with high compliance rates. Here, we aimed to perform a pilot study for acupoint herbal plaster treatment based on our previous microarray experience. Our laboratory has rich microarray experience that combines the Genomic Medicine Research Core Laboratory (GMRCL) [15], clinicians in the Department of Chinese Medicine at Chang Gung Memorial Hospital, and bioinformatics specialists. We performed chip analysis before and after acupuncture treatment in allergic rhinitis patients [16, 17]. We used cDNA microarray and oligonucleotide microarray analyses to investigate the influence of acupuncture on RNA expression profiles using blood samples from patients with allergic rhinitis. We used the RQLQ and statistical analysis to assess clinical outcomes [14]. The results of our microarray analysis were associated with the RQLQ to obtain our final conclusions.

Following exposure to allergens, allergic rhinitis patients exhibit immunoglobulin E (IgE), mast cell, and T helper (Th)2 lymphocyte immune responses related to (1) sensitization and memory, (2) the early phase, and (3) the late phase [18, 19]. The early phase can induce sneezing, nasal itching, runny and congested nasal passages, and other symptoms. The late phase contributes to patient fatigue, malaise, irritability, and other symptoms. Allergic rhinitis is regarded as an imbalanced Th1/Th2 cell-mediated response [20, 21]. Th1 cells primarily secrete IL-2, IFNγ, IL-3, and GM-CSF; whereas Th2 cells secrete IL-3, IL-4, IL-5, IL-10, IL-13, and GM-CSF [22]. Dominant Th2 cytokines can enhance allergen-specific IgE, which plays an important role in allergic inflammation [18, 20]. Studies using DNA microarray have indicated an imbalance in the T-helper cell-mediated immune system in patients with allergic rhinitis [23, 24]. Genes encoding chemokines and their receptors were elevated in this analysis; these genes play important roles in the Th2 response [24, 25].

According to our previous study, peripheral blood samples collected from allergic rhinitis patients before and after acupuncture treatment and analyzed by cDNA microarray analysis indicated an improvement in the counterbalance between pro-inflammatory cytokines derived from Th1 cells and anti-inflammatory cytokines derived from Th2 cells [16]. Nasal allergic reactions in patients with allergic rhinitis were inhibited by Th1 cells and were not promoted by Th2 cells following acupuncture treatment [16]. Although strengthening the Th1 response is regarded as a novel therapeutic target for allergic rhinitis, it has not yet been applied in clinical practice [19, 21]. We have published that acupuncture treatment may be another way to restructure Th1 and Th2 responses in patients with allergic rhinitis [16]. ImmunoCAP Phadiatop is a blood test widely used by ENT specialists in Taiwan to detect serum allergen-specific IgE antibodies [26, 27]. Among normal controls and atopic patients, the frequency of Ph-positive patients was 1 of 47 and 49 of 53, respectively [26]. In our previous study [17], Th1 and Th2 cells were suppressed after acupuncture treatment with group differences between Phadiatop (Ph)-positive and Ph-negative patients regarding gene expression characteristics and physiological responses. Studies have shown that the reduction in allergic inflammation and the restored Th1/Th2 (and Treg/Th2) equilibrium following acupuncture are sustained [17].

In this pilot study, we examined changes in gene expression associated with acupoint herbal plaster for allergic rhinitis. Using microarray, we compared gene expression levels in allergic rhinitis patients before and after a series of acupoint herbal plaster applications. This study applies EBM and supports the use of acupoint herbal therapy to treat allergic rhinitis.

Methods

Acupoint herbal plaster treatment

This pilot study was designed using an intervention model with single group assignment. Allergic rhinitis patients were included after their diagnoses were confirmed, and were treated with four applications of herbal plaster. The clinical portion of this study was conducted at the Department of Acupuncture and Moxibustion, Center for Traditional Chinese Medicine, Chang Gung Memorial Hospital from October 2009 to March 2010. Patients (age, 18–45 y) were eligible who met the following criteria: (1) exhibited sneezing, runny nose, and congestion for more than 9 months of the year [18]; (2) did not take medication in the previous month; and (3) provided written consent to enter a Chang Gung Memorial Hospital Institutional Review Board (IRB)-approved human trial. Patient diagnoses were confirmed by the following clinical and biochemical tests, which were performed by otolaryngologists: (1) physical examination; (2) anterior rhinoscopy; (3) ImmunoCAP Phadiatop (InVitroSight, Phadia AB, Uppsala, Sweden), determination of specified serum IgE antibodies to detect inhalant allergens [26, 27]. Patients were included in the trial after their initial diagnoses were confirmed [18, 28]. Patients with sinusitis or nasal polyps, or those who were unwilling or unable to complete the full course of treatment were excluded from the trial. All included patients were diagnosed with allergic rhinitis that was consistent with persistent allergic rhinitis according to ARIA’s new classification system. The ARIA system includes the following rhinitis symptoms and quality of life variables: duration, which includes intermittent or persistent allergic rhinitis; and nasal allergy symptoms, which must occur more than 4 days per week for 4 months per year to qualify as persistent allergic rhinitis [29, 30].

In total, 23 study patients received acupoint herbal plaster applications every 7–10 days over a 4-week period for a total of 4 applications. The herbal plaster consisted of mustard seed, fumarate, asarum, angelica, cinnamon, and ginger at a ratio of 3:3:2:2:0.5:4, respectively. The treatment was prepared by dissolving the ginger in water and adding the powder to form a plaster. Mixtures were formed into cakes of approximately 1.5 × 1.5 × 0.5 cm3 [13] and were held in position using plastic sheets. The following nine acupoints were selected: Dazhui (GV14), Feishu (BL13, both sides), Gaohuang (BL43, both sides), Shenshu (BL23, both sides), and Pishu (BL20, both sides). Each patching time lasted 1–3 h, depending on the patient’s tolerance. When drug cakes were removed, patients typically exhibited local skin redness and experienced slight burning sensations. Subsequent water exposure, including bathing, was avoided for 1–2 h following treatment to prevent skin aggravation. Patient drug tolerance varies, and adhering the cake for too long occasionally led to blisters. Blisters resulting from this treatment were coated with povidone iodine syrup and were protected with sterile gauze bandages.

Outcome evaluation

Clinical symptoms were indexed as follows: (1) assess symptoms before the first acupoint herbal plaster application, (2) determine rhinoconjunctivitis and rhinitis symptoms at the third and fourth acupoint herbal plaster applications. Clinical outcomes were evaluated using the RQLQ, which has been proven to be effective [14, 31] and includes 28 questions in 7 categories. The RQLQ was designed to measure the impact of rhinitis on quality of life. It considers that allergic rhinitis patients often are troubled by nasal symptoms, eye symptoms, sleep problems, emotional problems, social issues, and other symptoms [14, 29].

ImmunoCAP Phadiatop blood test

Prior to treatment at Chang Gung Memorial Hospital, all 23 allergic rhinitis patients were assessed by clinical pathologists using the ImmunoCAP Phadiatop blood test. Patients were evaluated for the presence of IgE antibodies against the following allergens: Dermatophagoides pteronyssinus, cat dander, dog dander, the German cockroach, and Moulds. Detection of IgE antibodies exceeding 0.35 kUA/L indicated a positive result.

RNA extraction and microarray

Patient peripheral blood samples were obtained in 5-ml volumes at the following 6 times (T0–T5) during the study: (1) before (T0) and 24 h after the first (T1) acupoint herbal plaster application; (2) before (T2) and 24 h after the third (T3) acupoint herbal plaster application; and (3) before the fourth (T4) and 24 h after the fourth (T5) acupoint herbal plaster application.

From each 5-ml blood sample, 2.5-ml aliquots were analyzed by the Clinical Pathology Department of Chang Gung Memorial Hospital for the following: complete blood count/differential count (CBC/DC):total white blood count; differential counts for neutrophils, lymphocytes, monocytes, eosinophils, and basophils; red blood cell count; platelet count; hemoglobin, hematocrit, and erythrocyte indices (mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, and red cell distribution width [RDW]). Total serum IgE levels were tracked before the first acupoint herbal plaster application and 24 h after the fourth acupoint herbal plaster application.

The remaining 2.5-ml blood samples were stored at room temperature in PAXgene Blood RNA collection tubes (Qiagen, Valencia, CA, USA), containing an RNA stabilizer. RNA was extracted from blood samples using the PAXgene Blood RNA System (Qiagen), according to the manufacturer’s recommendations, and samples were stored at −80 °C. RNA samples then were isolated using an RNeasy MinElute kit (Qiagen), and RNA quality and quantity were analyzed using a Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA).

Owing to the IRB’s limitation that no more than 5-ml peripheral blood could be collected from each study volunteer, we were unable to obtain sufficient RNA quantities to analyze individual participants. Therefore, we applied pre-amplification pooled mRNA samples to a single microarray chip, a method that has been used frequently in microarray analysis [23]. Although pooling could potentially confound signals by mixing cell populations and individuals, it avoids variation within individuals [32]. Because a microarray using pooled RNA only identifies genes that change dramatically, this approach highlights the most differentially expressed signaling pathways between diseased and control individuals [25]. In our study, equal quantities of mRNA were pooled from individuals with similar clinical diagnosis and IgE levels, thereby increasing RNA homogeneity. Each pooled sample corresponded to the blood RNA from 2 to 3 patients. Samples were analyzed using a GeneChip Human Genome U133 Plus2 array (Affymetrix, Santa Clara, CA, USA) containing approximately 54,675 probes. Samples from the 23 patients were divided into 7 pooled groups for each of the 6 blood collection time points and were applied to 42 chips.

Statistical analysis

Changes in RQLQ and IgE were compared to the first time point (T0; before first herbal plaster) via a paired Student’s t-test and a Mann Whitney U-test, respectively.

Microarray data analysis

Unsupervised (hierarchical clustering and principal component analysis) and supervised (Student’s t-test) methods have traditionally been used to analyze gene-expression data [33]. In this study, data were analyzed by hierarchical clustering using Cluster and TreeView software [34] with the following parameters: (1) standard deviation > 0.4 as the filtering cutoff point (1852 genes with marked changes selected among 35 arrays); (2) mean-centered genes and normalized genes; and (3) cluster analysis conducted using uncentered correlation of arrays. Cluster and TreeView programs were downloaded from http://bonsai.hgc.jp/~mdehoon/software/cluster. The Student’s t-test, Mann–Whitney U-test and PCA were performed using MATLAB version 7.4 and Statistics Toolbox version 3.1 (The MathWorks, Boston, MA, USA). A volcano plot was constructed using MATLAB to identify changes in replicate microarray data [35]. Specifically, the negative log of the p value (−log10[p value]) was plotted on the y-axis, and the log2 ratio of the fold change was plotted on the x-axis.

We evaluated genes that were differentially expressed following acupoint herbal plaster applications (T1, T2, T3, T4, T5, are compared with T0). Changes in specific gene expression before and after treatment could suggest potential immune mechanisms associated with acupoint herbal plaster application. RQLQ results were compared with gene expression differences in the final analysis.

Network visualization and analysis

The MetaCore analytical suite (GeneGo, St. Joseph, MI, USA) was used to compare differences in gene expression networks [3639]. MetaCore evaluates systems biology and drug development at the computational level, enabling analyses of human protein–protein interactions and mechanisms using the database. This suite contributes to analyses of regulatory networks and signaling pathway gene groups. To perform a network analysis of gene groups, MetaCore can work from an input list of genes and can randomly assign genes to different nodes to assess the probability of an interacting network [37]. In this study, the list of genes represented on the Affymetrix Human U133 Plus2 array was used as a base gene list to calculate p values using MetaCore procedures. MetaCore uses a hypergeometric model to determine significance [38, 39].

Results

Clinical outcomes of acupoint herbal plaster treatment

An otolaryngologist screened 23 study participants with allergic rhinitis, and the GMRCL conducted oligonucleotide chip experiments. Each participant’s diagnosis of perennial allergic rhinitis also was confirmed using anterior nasal endoscopy. Based on the results of an ImmunoCAP Phadiatop blood test of allergen-specific IgE, the 23 volunteers were classified as either Ph-positive (19 participants) or Ph-negative (4 participants) (Table 1). Assessments of clinical symptoms and IgE indices were performed before the first, third, and after the fourth acupoint herbal plaster application. The RQLQ was used to survey the patients, and the results were statistically analyzed for clinical symptoms [14] (Tables 2 and 3).
Table 1

Comparison of baseline characteristics between Ph-positive and Ph-negative patients before treatment

Variables

Ph-positive N = 19

SD

Ph-negative N = 4

SD

p Value

Mean

Mean

Gender

 Male

10

 

3

  

 Female

9

 

1

 

0.60^

Age

32.11

5.37

35

3.37

0.22

Duration of allergic rhinitis

  ≥ 10 years

14

 

3

  

  < 10 years

5

 

1

 

0.96^

Activity

3.12

1.39

3.08

1.32

0.66

Sleep

1.65

1.09

1.58

0,92

0.64

Non-hay fever symptoms

2.39

1.14

2.25

1.08

0.58

Practical problems

2.84

1.42

2.33

1.61

0.38

Nasal symptoms

2.78

1.17

2.94

1.43

0.98

Eye symptoms

2.37

1.41

1.75

1.14

0.24

Emotional symptoms

2.08

1.15

1.38

0.92

0.15

Overall score

2.46

1.02

2.19

0.96

0.40

IgE (Baseline)

302.12

78.75

21.25

7.70

0.002**

IgE (Follow-up)

333.61

86.01

25.10*

10.44

0.005**

SD Standard Deviation

Note: *p < 0:05, **p < 0:01 (Mann–Whitney U test)

^Fisher’s exact test

Table 2

Changes in RQLQ results following the third and fourth herbal plaster (hp) treatments in Ph-positive patients

Area of RQLQ

Baseline score

After 3rd hp score

P value (3rd hp vs. baseline)

After 4th hp score

P value (4th hp vs. baseline)

Activity

3.12

2.56

0.1322

2.09

0.0002**

Sleep

1.65

1.58

0.8488

1.35

0.0804

Non-hay fever symptoms

2.39

2.02

0.1465

1.64

0.0012**

Practical problems

2.84

2.39

0.1549

2.05

0.0018**

Nasal symptoms

2.78

2.30

0.1006

1.92

0.0000**

Eye symptoms

2.37

1.57

0.0330*

1.29

0.0066**

Emotional symptoms

2.08

1.62

0.0634

1.33

0.0010**

Overall score

2.46

2.00

0.0635

1.67

0.0000**

Paired Student’s t-test; n = 19, *p < 0.05 **p < 0.01

Table 3

Changes in RQLQ results following the third and fourth herbal plaster (hp) treatments in Ph-negative patients

Area of RQLQ

Baseline score

After 3rdhp score

P value (3rd hp vs. baseline)

After 4thhp score

P value (4th hp vs. baseline)

Activity

3.08

1.58

0.0577

1.33

0.0800

Sleep

1.58

1.58

1.0000

1.17

0.3677

Non-hay fever symptoms

2.25

1.79

0.3477

1.21

0.0564

Practical problems

2.33

1.67

0.3994

1.33

0.1135

Nasal symptoms

2.94

2.06

0.1881

1.31

0.0065**

Eye symptoms

1.75

1.19

0.4338

1.19

0.4594

Emotional symptoms

1.38

1.06

0.5551

0.69

0.0486*

Overall score

2.19

1.56

0.1940

1.18

0.0371*

Paired Student’s t-test; n = 4, *p < 0.05 **p < 0.01

In the Ph-positive group, the RQLQ results were compared before the first and after the fourth acupoint herbal plaster treatment. We identified significant improvements in six of the seven domains (activity, non-hay fever symptoms, eye symptoms, practical problems, nasal symptoms, and emotional symptoms) examined by the RQLQ (Tables 2 and 3). In the Ph-negative group, only two categories (nasal symptoms, emotional symptoms) appeared to improve following acupoint treatment. These results suggest that acupoint herbal plaster applications evoke distinct physiological responses in these two patient groups. These findings are consistent with our previous studies regarding acupuncture treatment for allergic rhinitis [16, 17].

Total serum IgE values were compared before the first and after the fourth acupoint herbal plaster application (Tables 4 and 5). Following the course of herbal plaster treatments, total IgE levels were unchanged in both the Ph-positive and -negative groups (Tables 4 and 5). This is consistent with previous short-term studies by our laboratory [16, 17] and others [40], which found that total serum IgE levels in allergic rhinitis patients treated with TCM did not change.
Table 4

Changes in total IgE levels following the fourth herbal plaster (hp) treatment in Ph-positive patients

 

No.

Baseline

Follow-up

P value^

Mean ± SD

Mean ± SD

IgE

19

302.12 ± 78.75

333.61 ± 86.01

0.085

SD Standard Deviation

^Mann–Whitney U-test

Table 5

Changes in patient total IgE levels following the fourth herbal plaster (hp) treatment in Ph-negative patients

 

No.

Baseline

Follow-up

P value^

Mean ± SD

Mean ± SD

IgE

4

21.25 ± 7.70

25.10 ± 10.44

0.63

SD Standard Deviation

^Mann–Whitney U-test

Ph-positive and Ph-negative allergic rhinitis patients exhibit distinct gene expression profiles following acupoint herbal plaster treatment

Since Ph-positive and Ph-negative groups exhibited different clinical outcomes, we explored the gene expression profiles of these two patient groups following acupoint herbal plaster treatment. Total RNA was extracted from peripheral blood samples at each of the 6 time points analyzed (23 patients, 138 RNA samples total). Because of insufficient blood RNA quantities (1–2 μg/subject), we pooled sets of 2–3 RNA samples from subjects with similar clinical indices, resulting in seven pooled RNA samples for each of the six time points. The 42 pooled RNA samples were applied to GeneChip Human Genome U133 Plus 2.0 arrays. Patient and sample information are detailed in Table 6.
Table 6

Pooling strategy for RNA samples. The first number in each cell indicates the group type, and the second indicates the time point (T0–T5 correspond to 1–6, respectively). A total of 42 chips were used. M, microarray chip

 

Before 1st herbal plaster (hp) (T0)

After 1st hp 24 h (T1)

Before 3rdhp (T2)

After 3rd hp 24 h (T3)

Before 4thhp (T4)

After 4th hp 24 h (T5)

Ph(+)

M1-1

M1-2

M1-3

M1-4

M1-5

M1-6

Ph(+)

M2-1

M2-2

M2-3

M2-4

M2-5

M2-6

Ph(+)

M3-1

M3-2

M3-3

M3-4

M3-5

M3-6

Ph(+)

M4-1

M4-2

M4-3

M4-4

M4-5

M4-6

Ph(+)

M5-1

M5-2

M5-3

M5-4

M5-5

M5-6

Ph(+)

M6-1

M6-2

M6-3

M6-4

M6-5

M6-6

Ph(−)

M7-1

M7-2

M7-3

M7-4

M7-5

M7-6

To estimate the effects of acupoint herbal plaster treatment, the gene expression level at each treatment point was subtracted from the first time point (T0; before herbal plaster treatment). After filtering the low-intensity non-significant genes (standard deviation < 0.4), 1852 genes remained for analysis with non-supervised hierarchical clustering methods. We identified distinct gene expression profiles in Ph-positive and -negative patients using a hierarchical approach (Fig. 1a). We further analyzed the correlation matrix for all 35 samples using a PCA [41]. The three-dimensional plot of the first three principal components by the matrix containing 80 % of the information is shown in Fig. 1b. This analysis indicated that the Ph-positive and -negative groups were distinct in their responses to acupoint herbal plaster treatment. Because the hierarchical clustering and PCA suggested that the M4-2 and M4-4 samples were outliers in the Ph-positive group, these samples were excluded from further analysis.
Fig. 1

Distinct gene expression profiles in Ph-positive and -negative patient groups as determined by a hierarchical clustering and b principle component analysis. a Each column represents a chip, and each row represents a specific gene. The gene expression level at each treatment point was subtracted from the first time point (T0). The color map uses red and green for high and low expression values, respectively. Black corresponds to genes exhibiting non-significant variation. b Three-dimensional plot of the first three principal components by the matrix containing 80 % of the information. Ph-positive and -negative patients are indicated as closed squares and open circles, respectively

Since, the clinical outcomes (RQLQ) after treatment in the Ph-positive and -negative groups differed, we explored the gene expression profiles for these two groups in response to acupoint herbal plaster application. We used a volcano plot to obtain an overview of the 1852 filtered genes (Fig. 2a), and we selected 89 genes that exhibited fold-changes exceeding 20.75 = 1.682 (p < 0.01, Student’s t-test) between Ph-positive and -negative participants (Fig. 2b and Table 7). These genes were examined using MetaCore software (http://lsresearch.thomsonreuters.com/pages/solutions/1/metacore) for reaction pathway analysis, and the pathways “Immune response_IL-13 signaling via JAK-STAT (Janus kinase and signal transducers and activators of transcription)” and “Inflammation_Interferon signaling” were identified to correspond to the down- and up-regulated genes, respectively, in the Ph-positive group (Fig. 2b and Table 8).
Fig. 2

a Volcano plot of the 1852 filtered genes and b functional and clustering analyses of the differentially expressed genes between Ph-positive and -negative groups. a In the volcano plot, the -log10(P value) is plotted on the y-axis, and the log2 ratio of the fold change is plotted on the x-axis. In total, 89 genes (red points) that exhibited fold-changes exceeding 20.75 = 1.682 between Ph-positive and -negative groups were selected from the 1852 filtered genes (p < 0.01, Student’s t-test). b The 89 differentially expressed genes were analyzed with MetaCore software, and “Immune response_IL-13 signaling via JAK-STAT” and “Inflammation_Interferon signaling” pathways were found to correspond to up- and down-regulated genes, respectively, in Ph-positive patients. The genes involved in pathway are indicated with arrows

Table 7

The 89 genes that were differentially expressed between Ph-positive and Ph-negative patients with allergic rhinitis following treatment with acupoint herbal paste

ID

Gene Symbol

Gene Title

Fold changea

P value

1552288_at

CILP2

cartilage intermediate layer protein 2

1.45

3.4E-05

1556590_s_at

NA

NA

1.32

1.4E-04

1557195_at

NA

NA

1.31

8.8E-04

1557761_s_at

LOC400794

hypothetical LOC400794

1.31

3.9E-06

1562216_at

NA

NA

1.30

1.7E-04

1565913_at

NA

NA

1.21

4.2E-10

1566134_at

CARHSP1

Calcium regulated heat stable protein 1, 24 kDa

1.20

6.5E-04

1566964_at

NA

NA

1.18

3.4E-04

1567240_x_at

OR2L2

olfactory receptor, family 2, subfamily L, member 2

1.11

7.1E-03

1569482_at

NA

NA

1.08

8.8E-03

200038_s_at

RPL17

ribosomal protein L17

1.08

7.4E-04

200082_s_at

RPS7

ribosomal protein S7

1.06

3.7E-03

200705_s_at

EEF1B2

eukaryotic translation elongation factor 1 beta 2

1.02

2.6E-03

200986_at

SERPING1

serpin peptidase inhibitor, clade G (C1 inhibitor), member 1

1.02

2.0E-03

201699_at

PSMC6

proteasome (prosome, macropain) 26S subunit, ATPase, 6

1.01

4.0E-03

202086_at

MX1

myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 (mous

1.01

7.2E-09

202411_at

IFI27

interferon, alpha-inducible protein 27

1.00

7.8E-05

202635_s_at

POLR2K

polymerase (RNA) II (DNA directed) polypeptide K, 7.0 kDa

0.99

1.4E-03

204286_s_at

PMAIP1

phorbol-12-myristate-13-acetate-induced protein 1

0.98

5.5E-09

204415_at

IFI6

interferon, alpha-inducible protein 6

0.97

7.6E-05

204439_at

IFI44L

interferon-induced protein 44-like

0.96

2.0E-03

204732_s_at

TRIM23

tripartite motif-containing 23

0.93

1.7E-03

205849_s_at

UQCRB

ubiquinol-cytochrome c reductase binding protein

0.91

7.7E-03

205914_s_at

GRIN1

glutamate receptor, ionotropic, N-methyl D-aspartate 1

0.90

1.5E-03

206584_at

LY96

lymphocyte antigen 96

0.90

1.2E-04

207723_s_at

KLRC3

killer cell lectin-like receptor subfamily C, member 3

0.88

3.6E-04

208792_s_at

CLU

clusterin

0.88

3.5E-03

209160_at

AKR1C3

aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, t

0.88

3.9E-06

209651_at

TGFB1I1

transforming growth factor beta 1 induced transcript 1

0.86

1.0E-03

209732_at

CLEC2B

C-type lectin domain family 2, member B

0.86

3.7E-03

209743_s_at

ITCH

itchy E3 ubiquitin protein ligase homolog (mouse)

0.85

2.3E-03

209795_at

CD69

CD69 molecule

0.85

3.9E-08

210103_s_at

FOXA2

forkhead box A2

0.84

9.9E-04

210432_s_at

SCN3A

sodium channel, voltage-gated, type III, alpha subunit

0.83

2.8E-04

210548_at

CCL23

chemokine (C-C motif) ligand 23

0.83

8.5E-05

210639_s_at

ATG5

ATG5 autophagy related 5 homolog (S. cerevisiae)

0.82

1.7E-07

210873_x_at

APOBEC3A

apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3A

0.82

2.7E-04

211968_s_at

HSP90AA1

heat shock protein 90 kDa alpha (cytosolic), class A member 1

0.81

8.0E-05

212270_x_at

RPL17

ribosomal protein L17

0.81

2.9E-04

212537_x_at

RPL17

ribosomal protein L17

0.78

1.6E-03

213226_at

CCNA2

cyclin A2

0.78

4.2E-03

214070_s_at

ATP10B

ATPase, class V, type 10B

0.78

3.3E-03

215101_s_at

CXCL5

chemokine (C-X-C motif) ligand 5

0.78

6.0E-03

215394_at

PIK3C3

phosphoinositide-3-kinase, class 3

0.77

6.3E-10

215646_s_at

VCAN

versican

0.77

4.3E-04

216412_x_at

LOC100290557

similar to hCG91935

0.77

1.3E-03

216834_at

RGS1

regulator of G-protein signaling 1

0.76

2.3E-03

217915_s_at

RSL24D1

ribosomal L24 domain containing 1

0.76

9.8E-04

219519_s_at

SIGLEC1

sialic acid binding Ig-like lectin 1, sialoadhesin

0.76

4.7E-04

219551_at

EAF2

ELL associated factor 2

0.76

3.1E-03

220141_at

C11orf63

chromosome 11 open reading frame 63

0.75

5.8E-03

220184_at

NANOG

Nanog homeobox

−0.75

3.9E-03

220646_s_at

KLRF1

killer cell lectin-like receptor subfamily F, member 1

−0.75

3.9E-11

220827_at

NA

NA

−0.76

1.6E-03

222229_x_at

RPL26

ribosomal protein L26

−0.77

5.9E-05

222465_at

RSL24D1

ribosomal L24 domain containing 1

−0.78

1.5E-03

223963_s_at

IGF2BP2

insulin-like growth factor 2 mRNA binding protein 2

−0.79

2.5E-04

224293_at

TTTY10

testis-specific transcript, Y-linked 10 (non-protein coding)

−0.79

8.6E-03

225541_at

RPL22L1

ribosomal protein L22-like 1

−0.80

4.7E-03

226344_at

ZMAT1

zinc finger, matrin type 1

−0.81

1.4E-04

227454_at

TAOK1

TAO kinase 1

−0.81

9.4E-04

227766_at

LIG4

ligase IV, DNA, ATP-dependent

−0.82

9.9E-03

228174_at

SCAI

suppressor of cancer cell invasion

−0.83

8.5E-03

228439_at

BATF2

basic leucine zipper transcription factor, ATF-like 2

−0.83

9.6E-03

228970_at

ZBTB8OS

zinc finger and BTB domain containing 8 opposite strand

−0.86

1.1E-07

229431_at

RFXAP

regulatory factor X-associated protein

−0.86

8.8E-03

229437_at

MIR155HG

MIR155 host gene (non-protein coding)

−0.87

4.5E-04

229893_at

FRMD3

FERM domain containing 3

−0.89

7.0E-03

229910_at

SHE

Src homology 2 domain containing E

−0.89

2.0E-03

230153_at

NEK9

NIMA (never in mitosis gene a)- related kinase 9

−0.89

6.2E-09

231014_at

TRIM50

tripartite motif-containing 50

−0.89

4.8E-03

231038_s_at

NA

NA

−0.92

8.1E-03

231484_at

NA

NA

−0.92

1.5E-04

231688_at

MMP8

matrix metallopeptidase 8 (neutrophil collagenase)

−0.93

6.4E-03

231975_s_at

MIER3

mesoderm induction early response 1, family member 3

−0.94

1.9E-03

233015_at

MBNL1

muscleblind-like (Drosophila)

−0.96

3.7E-03

235762_at

TAS2R14

taste receptor, type 2, member 14

−0.97

8.7E-05

236495_at

NA

NA

−0.97

8.1E-10

236666_s_at

LRRC10B

leucine rich repeat containing 10B

−0.98

1.1E-05

237689_at

SARS

Seryl-tRNA synthetase

−1.00

1.8E-03

238174_at

NA

NA

−1.01

6.3E-03

238918_at

NA

NA

−1.06

1.7E-03

239655_at

NA

NA

−1.07

4.2E-03

239819_at

NA

NA

−1.08

1.4E-04

240145_at

NA

NA

−1.10

5.3E-03

240262_at

NA

NA

−1.11

4.2E-05

240652_at

NA

NA

−1.20

8.0E-10

240866_at

NA

NA

−1.26

3.8E-03

242625_at

RSAD2

radical S-adenosyl methionine domain containing 2

−1.43

2.0E-03

NA Not Available

afold change (Log2 ratio)

Table 8

Metacore process map for the 89 genes that were differentially expressed between Ph-positive and Ph-negative patients with allergic rhinitis following acupoint herbal paste treatment

Process map of down-regulated genes in Ph(+)

Maps

P value

Filter Genesa

Map genesb

DNA damage_NHEJ mechanisms of DSBs repair

1.4E-02

1 (LIG4)

19

Neurophysiological process_Bitter taste signaling

2.0E-02

1 (TAS2R14)

28

Apoptosis and survival_Granzyme A signaling

2.1E-02

1 (LIG4)

30

Cell cycle_Role of Nek in cell cycle regulation

2.3E-02

1 (NEK9)

32

Development_Role of Activin A in cell differentiation and proliferation

2.9E-02

1 (NANOG)

40

Immune response_IL-13 signaling via JAK-STAT

3.1E-02

1 (MMP8)

44

Process map of up-regulated genes in Ph(+)

Maps

P value

Filter Genesa

Map genesb

Inflammation_Interferon signaling

1.1E-02

3 (IFI6,IFI27, MX1)

110

Autophagy_Autophagy

2.3E-02

2 (PIK3C3,ATG5)

55

Cell cycle_S phase

2.6E-02

2 (HSP90AA1, CCNA2)

149

aNumber of filter genes in the map

bNumber of genes in the map

Differentially expressed genes after acupoint herbal plaster treatment in Ph-positive patients

The RQLQ indicated that the clinical efficacy of herbal plaster treatment was different between Ph-positive patients and Ph-negative patients. Then we evaluated genes that were differentially expressed following acupoint herbal plaster applications (T1, T2, T3, T4, T5, are compared with T0) in Ph-positive patients. Since the differentially expresse in Ph-positive group is less than Ph-positive group compared with Ph-negative group. We selected 47 genes that exhibited p < 0.01 (via Student’s t-test) and fold changes (vs. T0) of 20.4 = 1.320 (Fig. 3 and Table 9). Globally, most genes were down-regulated (45/47) after herbal plaster treatment. This result was consistent with our previous report that most genes were down-regulated after acupuncture treatment in Ph-positive allergic rhinitis patients [17].
Fig. 3

a Volcano plot of the gene expression profiles in the Ph-positive group and b differentially expressed genes (compared with T0) subjected to hierarchical clustering analysis. a In the volcano plot, the -log10(P value) is plotted on the y-axis, and the log2 ratio of the fold change is plotted on the x-axis. Forty-seven genes (red points) that exhibited fold-changes of 20.4 = 1.320 (p < 0.01) were selected from the 1852 filtered genes. b In the cluster plot, each column represents a chip, and each row represents a specific gene. Most genes were down-regulated (45/47 genes) among the differentially expressed genes after herbal plaster treatment. The genes involved in pathway are indicated with arrows

Table 9

The 47 genes that were differentially expressed as compared to the first time point (T0; before herbal plaster treatment in the Ph-positive group)

ID

Gene Symbol

Gene Title

Fold changea

P value

211969_at

HSP90AA1

heat shock protein 90 kDa alpha (cytosolic), class A member 1

−0.62

5.4E-10

224567_x_at

MALAT1

Metastasis associated lung adenocarcinoma transcript 1 (non-protein coding)

−0.62

3.3E-06

226675_s_at

MALAT1

Metastasis associated lung adenocarcinoma transcript 1 (non-protein coding)

−0.58

1.0E-04

216563_at

ANKRD12

Ankyrin repeat domain 12

−0.58

2.8E-04

222465_at

RSL24D1

ribosomal L24 domain containing 1

−0.58

1.6E-06

204732_s_at

TRIM23

tripartite motif-containing 23

−0.56

2.8E-07

201304_at

NDUFA5

NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 5, 13 kDa

−0.52

6.9E-07

203491_s_at

CEP57

centrosomal protein 57 kDa

−0.52

3.5E-06

235643_at

SAMD9L

sterile alpha motif domain containing 9-like

−0.52

1.7E-04

209662_at

CETN3

centrin, EF-hand protein, 3 (CDC31 homolog, yeast)

−0.51

2.3E-04

212417_at

SCAMP1

secretory carrier membrane protein 1

−0.50

4.5E-04

217915_s_at

RSL24D1

ribosomal L24 domain containing 1

−0.49

2.6E-06

200598_s_at

HSP90B1

heat shock protein 90 kDa beta (Grp94), member 1

−0.49

3.6E-07

242429_at

ZNF567

zinc finger protein 567

−0.49

1.8E-05

232958_at

NA

NA

−0.48

5.6E-05

222326_at

NA

NA

−0.48

2.0E-05

200026_at

RPL34

ribosomal protein L34

−0.47

3.1E-03

221765_at

UGCG

UDP-glucose ceramide glucosyltransferase

−0.47

3.1E-04

212794_s_at

KIAA1033

KIAA1033

−0.46

1.0E-06

200099_s_at

RPS3A

ribosomal protein S3A

−0.46

2.2E-04

203153_at

IFIT1

interferon-induced protein with tetratricopeptide repeats 1

−0.46

2.9E-04

211968_s_at

HSP90AA1

heat shock protein 90 kDa alpha (cytosolic), class A member 1

−0.45

5.6E-06

226800_at

EFCAB7

EF-hand calcium binding domain 7

−0.45

9.2E-09

225312_at

COMMD6

COMM domain containing 6

−0.44

6.1E-03

201699_at

PSMC6

proteasome (prosome, macropain) 26S subunit, ATPase, 6

−0.44

4.4E-07

222848_at

CENPK

centromere protein K

−0.44

2.4E-05

212587_s_at

PTPRC

protein tyrosine phosphatase, receptor type, C

−0.43

1.7E-04

219239_s_at

ZNF654

zinc finger protein 654

−0.43

3.0E-07

205849_s_at

UQCRB

ubiquinol-cytochrome c reductase binding protein

−0.43

2.7E-03

214453_s_at

IFI44

interferon-induced protein 44

−0.43

6.8E-05

227152_at

C12orf35

chromosome 12 open reading frame 35

−0.43

7.2E-05

200061_s_at

RPS24

ribosomal protein S24

−0.42

5.8E-03

205809_s_at

WASL

Wiskott-Aldrich syndrome-like

−0.42

4.0E-05

222616_s_at

USP16

ubiquitin specific peptidase 16

−0.42

6.0E-07

219356_s_at

CHMP5

chromatin modifying protein 5

−0.42

2.4E-05

244042_x_at

NA

NA

−0.41

4.0E-05

205871_at

PLGLA

plasminogen-like A

−0.41

1.4E-06

235653_s_at

THAP6

THAP domain containing 6

−0.41

1.7E-06

219387_at

CCDC88A

coiled-coil domain containing 88A

−0.41

6.8E-05

202110_at

COX7B

cytochrome c oxidase subunit VIIb

−0.41

4.0E-03

209795_at

CD69

CD69 molecule

−0.41

4.5E-05

224786_at

SCOC

short coiled-coil protein

−0.40

2.4E-03

221728_x_at

XIST

X (inactive)-specific transcript (non-protein coding)

−0.40

3.2E-05

214218_s_at

XIST

X (inactive)-specific transcript (non-protein coding)

−0.40

3.9E-04

212391_x_at

RPS3A

ribosomal protein S3A

−0.40

3.6E-04

202411_at

IFI27

interferon, alpha-inducible protein 27

0.41

6.5E-03

228582_x_at

MALAT1

Metastasis associated lung adenocarcinoma transcript 1 (non-protein coding)

0.49

5.8E-03

NA Not Available

afold change (Log2 ratio)

These 45 genes then were input to the MetaCore reaction pathways analysis. The data indicated that Ph-positive allergic rhinitis patients who received acupoint herbal plaster applications significantly induced several pathways (p < 0.01; Table 10). Among the 45 down-regulated genes, pathway analysis identified significant involvement of the “Oxidative phosphorylation pathway” (p < 0.0001). Network analysis also identified “Protein folding_Response to unfolded proteins,” “Immune response Antigen presentation,” and “Immune response Phagosome in antigen presentation” as significant (p < 0.001) relative to the 45 down-regulated genes.
Table 10

Metacore process map for the 45 genes that were down-regulated in Ph-positive patients with allergic rhinitis following acupoint herbal paste treatment

Process map of down-regulated genes in Ph(+)

Maps

P value

Filter Genesa

Map genesb

Protein folding_Response to unfolded proteins

2.3E-04

2 (HSP90AA1, HSP90B1)

69

Immune response_Antigen presentation

3.3E-04

3 (PTPRC, HSP90AA1, HSP90B1)

197

Immune response_Phagosome in antigen presentation

7.4E-04

3 (WASL, HSP90AA1, HSP90B1)

243

aNumber of filter genes in the map

bNumber of genes in the map

Discussion

Allergic rhinitis likely results from an imbalance in the Th1 and Th2 cell-mediated inflammatory responses [20, 21]. In addition to the hygiene hypothesis causing deviation of the Th1 and Th2 balance and reduced immune suppression, investigators have implicated decreases in T-regulatory (Treg) activity in allergy diseases [42, 43]. People suffering from allergies, usually have a reduced Th1 reaction and a predominant Th2 response. Th1 cells tended to decrease in patients with allergic rhinitis, whereas Th2 cells were significantly increased. Significant deviations from the normal Th1/Th2 ratio may be associated with the incidence of allergic diseases [18, 20, 44]. A study examining allergic inflammation that focused on Th2 cytokines (IL-4, IL-5, IL-9, and IL-13) reported that these cytokines recruited cells that induced allergic inflammation via chemokine secretion [44]. Few reports have described human allergic inflammation with respect to cytokine antagonists [19, 21, 45]. Although strengthening the Th1 response is regarded as a novel therapeutic approach for allergic rhinitis, this method has not been applied clinically [19, 21]. A restructuring of the Th1 and Th2 responses in patients with allergic rhinitis may be accomplished with acupuncture [16, 17]. Studies have shown that acupuncture treatment of allergic inflammation can maintain the equilibrium between Th1 and Th2 cells and between Tregs and Th2 cells [16, 17].

Many patients choose acupoint herbal plaster treatments for allergic rhinitis in Taiwan [35] and mainland China [6, 7]. We previously examined the efficacy of acupoint herbal plaster treatment for allergic rhinitis [13]. The present study is the first to apply the RQLQ to comprehensively assess the effects of acupoint herbal plaster on allergic rhinitis symptoms. Our results suggest that acupoint herbal plaster is a safe, effective, and convenient treatment for allergic rhinitis. A comparison of baseline characteristics before treatment between Ph-positive and Ph-negative patients showed no differences, with the exception of total IgE levels (Table 1). The RQLQ results after the fourth treatment of 19 Ph-positive patients indicated symptom improvements in six of seven categories (activity, non-hay fever symptoms, practical problems, nasal symptoms, eye symptoms, emotional symptoms; Tables 2 and 3). In contrast, the four Ph-negative volunteers (−) reported symptom improvements in only two categories (nasal symptoms, emotional symptoms; Tables 2 and 3). These results are similar to those found in our previous report on acupuncture treatment for allergic rhinitis [16, 17]; however, the herbal plaster treatment was noninvasive and easy to apply. The degree of symptom improvement among Ph-positive allergic rhinitis patients was different with the Ph-negative group, indicating that the acupoint herbal plaster treatment in these patient groups evoked distinct physiological responses. Due to its preliminary nature, this study has some limitations including the lack of a control group or a safety assessment.

In this study, the average total serum IgE levels tended to increase in Ph-positive and -negative groups following the fourth herbal plaster treatment, but the changes were not statistically significant (Table 4 and 5). This result is similar to that of our previous acupuncture study [16, 17] and may indicate that reducing total IgE synthesis is not the primary mechanism of acupoint herbal plaster treatment of allergic rhinitis.

The Ph-positive and -negative groups exhibited different gene expression trends after acupoint herbal plaster treatment (Fig. 2 and Table 7). This supports the results of the RQLQ, and indicates that the patient groups respond differently to acupoint herbal plaster.

Pathway analysis of the differentially expressed genes indicated that “Immune response_IL-13 signaling via JAK-STAT” and “Inflammation_Interferon signaling” pathways corresponded to down- and up-regulated genes, respectively, between Ph-positive and Ph-negative patients (Fig. 2b and Table 8). Since a Th1/Th2 cytokine imbalance contributes to the etiology and pathogenesis of allergic rhinitis, understanding the mechanisms of this disease will help to find novel targets for therapy. Th1 cells secrete primarily IL-2, IFNγ, IL-3, and GM-CSF, whereas Th2 cells secrete IL-3, IL-4, IL-5, IL-10, IL-13, and GM-CSF [22]. Cytokines released after activation of T-cell receptors interact with cytokine receptors on mononuclear cells and activate these cells via the JAK-STAT (Janus kinase and signal transducers and activators of transcription) pathway. The JAK-STAT pathway is involved in histamine-mediated regulation of the Th2 cytokines IL-5, IL-10, and IL-13, and of the Th1 cytokine IFNγ [22]. IL-13 plays a central role in the promotion of an allergic inflammatory eosinophilic reaction in allergic diseases via IgE isotype switching. IFNγ down-regulates the secretion of certain Th2 cytokines [22]. Local administration of IFNγ in mice prevented antigen-induced eosinophil infiltration into the trachea and normalized airway function. However, recombinant subcutaneous administration of IFNγ had no benefit in the treatment of steroid-dependent asthma [22]. Pathways that downregulated IL-13 signaling via JAK-STAT and upregulated Interferon signaling pathways were differentially expressed between Ph-positive and Ph-negative patients with allergic rhinitis after acupoint herbal paste treatment; however, further studies are necessary to confirm these results.

Several pathways were significantly induced in Ph-positive allergic rhinitis patients who received acupoint herbal plaster applications. Phagosomal immune response in antigen presentation was noted due to an immune response to the herbal plater treatment (Table 10). Macrophages function to clear infectious particles, and this process involves engulfing microbes into phagosomes where they are lysed and degraded. Phagosomes are pivotal in linking both the innate and adaptive immune responses [46]. Phagosomal proteins regulated by IFNγ include proteins expected to alter phagosome maturation, enhance microbe degradation, trigger the macrophage immune response, and promote antigen loading on major histocompatibility complex (MHC) class I molecules [46]. IFNγ delays phagosomal acquisition of lysosomal hydrolases and peptidases to aid in antigen presentation, which is dependent on phagosomal networks of the actin cytoskeleton and vesicle-trafficking proteins, as well as Src kinases and calpain proteases [47].

In this preliminary study, Ph-positive patients with allergic rhinitis who received acupoint herbal plaster treatments manifested gene expression changes involved in the “Immune response_IL-13 signaling via JAK-STAT” pathway. These patients reported improved clinical symptoms of allergic rhinitis according to the RQLQ scale. Pathway analysis suggested that allergic rhinitis patients treated with acupoint herbal plaster improved their balance of Th1-derived pro-inflammatory cytokines versus Th2-derived anti-inflammatory cytokines. Our results indicate that acupoint herbal plaster application diminished allergic inflammation by maintaining an appropriate equilibrium between Th1 and Th2 cells.

Conclusions

RQLQ and gene expression profiles indicated that patients with Ph-positive and -negative allergic rhinitis exhibit distinct physiological responses after receiving acupoint herbal plaster treatments. Gene expression levels were compared before and after acupoint herbal plaster application and in Ph-positive versus Ph-negative participants. In this preliminary study, we find that the IL-13 immune response via JAK-STAT signaling and interferon inflammation signaling were down- and upregulated, respectively, in the Ph-positive group. Further studies are required to verify these pathways in Ph-positive patients, and to determine the mechanism of such pathway dysregulation.

Declarations

Acknowledgements

We thank the National Science Council NSC 97-3112-B-001-020 by the National Research Program for Genomic Medicine for assistance with statistical analyses, the Genomic Medicine Research Core Laboratory of Chang Gung Memorial Hospital provided technical assistance.

Funding

This study was supported by Chang Gung Medical Research Project CMRPG 380661 and CMRPG 380662, and by CMU under the Aim for Top University Plan of the Ministry of Education, Taiwan and is supported in part by Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW105-TDU-B-212-133019) .

Availability of data and materials

The datasets analyzed during the current study are presented in the manuscript or available on reasonable request from the corresponding author of this manuscript (Hen-Hong Chang) at Email: tcmchh55@gmail.com.

Authors’ contributions

SHS, LYS, and CHH conceived the study and designed the study protocol. SHS and LYS wrote the manuscript. CHH and TCN revised study protocols and wrote several sections of the manuscript. CHH and SHS coordinated and directed study implementation. LYS and TCN helped to develop study measures as well as data analysis and interpretation. All authors contributed to drafting the manuscript and have read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interest.

Consent for publication

All authors have read and agreed to all the contents for publication.

Ethics approval and consent to participate

This human trial was approved by Chang Gung Memorial Hospital Institutional Review Board (IRB). All participants provided written consent forms.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Chang Gung Memorial Hospital and Chang Gung University College of Medicine
(2)
Department of Biotechnology, Ming Chuan University
(3)
School of Post-Baccalaureate Chinese Medicine, and Research Center for Chinese Medicine and Acupuncture, China Medical University
(4)
Departments of Chinese Medicine, China Medical University Hospital

References

  1. Swartzman LC, Harshman RA, Burkell J, Lundy ME. What Accounts for the Appeal of Complementary/Alternative Medicine, and What Makes Complementary/Alternative Medicine “Alternative”? Med Decis Making. 2002;22(5):431–50.View ArticlePubMedGoogle Scholar
  2. Passalacqua G, Bousquet PJ, Carlsen KH, Kemp J, Lockey RF, Niggemann B, Pawankar R, Price D, Bousquet J. ARIA update: I--Systematic review of complementary and alternative medicine for rhinitis and asthma. J Allergy Clin Immunol. 2006;117(5):1054–62.View ArticlePubMedGoogle Scholar
  3. Tai CJ, Chien LY. The treatment of allergies using Sanfujiu: A method of applying Chinese herbal medicine paste to acupoints on three peak summer days. Am J Chin Med. 2004;32(6):967–76.View ArticlePubMedGoogle Scholar
  4. Tai CJ, Chang CP, Huang CY, Chien LY. Efficacy of sanfujiu to treat allergies: patient outcomes at 1 year after treatment. Evid Based Complement Alternat Med. 2007;4(2):241–6.View ArticlePubMedGoogle Scholar
  5. Hsu WH, Ho TJ, Huang CY, Ho HC, Liu YL, Liu HJ, Lai NS, Lin JG. Chinese medicine acupoint herbal patching for allergic rhinitis: a randomized controlled clinical trial. Am J Chin Med. 2010;38(4):661–73.View ArticlePubMedGoogle Scholar
  6. Wu X, Peng J, Li G, Zhang W, Liu G, Liu B. Efficacy evaluation of summer acupoint application treatment on asthma patients: a two-year follow-up clinical study. J Tradit Chin Med. 2015;35(1):21–7.View ArticlePubMedGoogle Scholar
  7. Zhou F, Yang D, Lu J-y, Li Y-f, Gao K-y, Zhou Y-j, Yang R-x, Cheng J, Qi X-x, Lai L, et al. Characteristics of clinical studies of summer acupoint herbal patching: a bibliometric analysis. BMC Complement Altern Med. 2015;15(1):1–10.View ArticleGoogle Scholar
  8. China association of Acupuncture-Moxibustion, Guideline of application of ‘Winter diseases treated in summer’ Herbal patch(draf). Chin Acupunct Moxibustion. 2009;07:541–2.Google Scholar
  9. Wen CY, Liu YF, Zhou L, Zhang HX, Tu SH. A Systematic and Narrative Review of Acupuncture Point Application Therapies in the Treatment of Allergic Rhinitis and Asthma during Dog Days. Evid Based Complement Alternat Med. 2015;2015:846851.PubMedPubMed CentralGoogle Scholar
  10. Chen X, Lu C, Stålsby-Lundborg C, Li Y, Li X, Sun J, Ouyang W, Li G, et al. Efficacy and Safety of Sanfu Herbal Patch at Acupoints for Persistent Allergic Rhinitis: Study Protocol for a Randomized Controlled Trial. Evid Based Complement Altern Med. 2015;2015:10.Google Scholar
  11. Zhou F, Yan LJ, Yang GY, Liu JP. Acupoint herbal patching for allergic rhinitis: a systematic review and meta-analysis of randomised controlled trials. Clin Otolaryngol. 2015;40(6):551–68.View ArticlePubMedGoogle Scholar
  12. Xue CC, Li CG, Hugel HM, Story DF. Does acupuncture or Chinese herbal medicine have a role in the treatment of allergic rhinitis? Curr Opin Allergy Clin Immunol. 2006;6(3):175–9.View ArticlePubMedGoogle Scholar
  13. Chang Y-C, Shiue H-S, Chang H-H, Chang C-H, Yang Y-L, Yen H-R. The therapeutic effect of appllying herbal paste onto acupoints for allergic rhinitis during dog days - a preliminary study. J Chin Med. 2006;17(1–2):15–24.Google Scholar
  14. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991;21(1):77–83.View ArticlePubMedGoogle Scholar
  15. Wang TH, Lee YS, Chen ES, Kong WH, Chen LK, Hsueh DW, Wei ML, Wang HS. Establishment of cDNA microarray analysis at the Genomic Medicine Research Core Laboratory (GMRCL) of Chang Gung Memorial Hospital. Chang Gung Med J. 2004;27(4):243–60.PubMedGoogle Scholar
  16. Shiue HS, Lee YS, Tsai CN, Hsueh YM, Sheu JR, Chang HH. DNA microarray analysis of the effect on inflammation in patients treated with acupuncture for allergic rhinitis. J Altern Complement Med. 2008;14(6):689–98.View ArticlePubMedGoogle Scholar
  17. Shiue HS, Lee YS, Tsai CN, Hsueh YM, Sheu JR, Chang HH. Gene expression profile of patients with phadiatop-positive and -negative allergic rhinitis treated with acupuncture. J Altern Complement Med. 2010;16(1):59–68.View ArticlePubMedGoogle Scholar
  18. Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol. 2001;108(1 Suppl):S2–8.View ArticlePubMedGoogle Scholar
  19. Valenta R. The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol. 2002;2(6):446–53.PubMedGoogle Scholar
  20. Benson M, Adner M, Cardell LO. Cytokines and cytokine receptors in allergic rhinitis: how do they relate to the Th2 hypothesis in allergy? Clin Exp Allergy. 2001;31(3):361–7.View ArticlePubMedGoogle Scholar
  21. Holgate ST, Broide D. New targets for allergic rhinitis--a disease of civilization. Nat Rev Drug Discov. 2003;2(11):902–14.View ArticlePubMedGoogle Scholar
  22. Packard KA, Khan MM. Effects of histamine on Th1/Th2 cytokine balance. Int Immunopharmacol. 2003;3(7):909–20.View ArticlePubMedGoogle Scholar
  23. Benson M, Carlsson B, Carlsson LM, Mostad P, Svensson PA, Cardell LO. DNA microarray analysis of transforming growth factor-beta and related transcripts in nasal biopsies from patients with allergic rhinitis. Cytokine. 2002;18(1):20–5.View ArticlePubMedGoogle Scholar
  24. Zhang JH, Cao XD, Lie J, Tang WJ, Liu HQ, Fenga XY. Neuronal specificity of needling acupoints at same meridian: a control functional magnetic resonance imaging study with electroacupuncture. Acupunct Electrother Res. 2007;32(3–4):179–93.View ArticlePubMedGoogle Scholar
  25. Benson M, Jansson L, Adner M, Luts A, Uddman R, Cardell LO. Gene profiling reveals decreased expression of uteroglobin and other anti-inflammatory genes in nasal fluid cells from patients with intermittent allergic rhinitis. Clin Exp Allergy. 2005;35(4):473–8.View ArticlePubMedGoogle Scholar
  26. Eriksson NE. Allergy screening with Phadiatop and CAP Phadiatop in combination with a questionnaire in adults with asthma and rhinitis. Allergy. 1990;45(4):285–92.View ArticlePubMedGoogle Scholar
  27. Liu YH, Chou HH, Jan RL, Lin HJ, Liang CC, Wang JY, Wu YC, Shieh CC. Comparison of two specific allergen screening tests in different patient groups. Acta Paediatr Taiwan. 2006;47(3):116–22.PubMedGoogle Scholar
  28. Group IRMW. International Consensus Report on the diagnosis and management of rhinitis. International Rhinitis Management Working Group. Allergy. 1994;49(19 Suppl):1–34.Google Scholar
  29. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(5 Suppl):S147–334.View ArticlePubMedGoogle Scholar
  30. Bachert C, van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. In collaboration with the World Health Organization. Executive summary of the workshop report. 7–10 December 1999, Geneva, Switzerland. Allergy. 2002;57(9):841–55.View ArticlePubMedGoogle Scholar
  31. Juniper EF, Stahl E, Doty RL, Simons FE, Allen DB, Howarth PH. Clinical outcomes and adverse effect monitoring in allergic rhinitis. J Allergy Clin Immunol. 2005;115(3 Pt 2):S390–413.View ArticlePubMedGoogle Scholar
  32. Benson M, Svensson PA, Carlsson B, Jernas M, Reinholdt J, Cardell LO, Carlsson L. DNA microarrays to study gene expression in allergic airways. Clin Exp Allergy. 2002;32(2):301–8.View ArticlePubMedGoogle Scholar
  33. Quackenbush J. Computational analysis of microarray data. Nat Rev Genet. 2001;2(6):418–27.View ArticlePubMedGoogle Scholar
  34. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998;95(25):14863–8.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Cui X, Churchill GA. Statistical tests for differential expression in cDNA microarray experiments. Genome Biol. 2003;4(4):210.View ArticlePubMedPubMed CentralGoogle Scholar
  36. Nikolsky Y, Ekins S, Nikolskaya T, Bugrim A. A novel method for generation of signature networks as biomarkers from complex high throughput data. Toxicol Lett. 2005;158(1):20–9.View ArticlePubMedGoogle Scholar
  37. Mason CW, Swaan PW, Weiner CP. Identification of interactive gene networks: a novel approach in gene array profiling of myometrial events during guinea pig pregnancy. Am J Obstet Gynecol. 2006;194(6):1513–23.View ArticlePubMedGoogle Scholar
  38. Winn ME, Zapala MA, Hovatta I, Risbrough VB, Lillie E, Schork NJ. The effects of globin on microarray-based gene expression analysis of mouse blood. Mamm Genome. 2010;21(5–6):268–75.View ArticlePubMedPubMed CentralGoogle Scholar
  39. Falcon S, Gentleman R. Using GOstats to test gene lists for GO term association. Bioinformatics. 2007;23(2):257–8.View ArticlePubMedGoogle Scholar
  40. Xue CC, Thien FC, Zhang JJ, Da Costa C, Li CG. Treatment for seasonal allergic rhinitis by Chinese herbal medicine: a randomized placebo controlled trial. Altern Ther Health Med. 2003;9(5):80–7.PubMedGoogle Scholar
  41. Raychaudhuri S, Stuart JM, Altman RB. Principal components analysis to summarize microarray experiments: application to sporulation time series. Pac Symp Biocomput. 2000;455–466.Google Scholar
  42. Romagnani S. Immunologic influences on allergy and the TH1/TH2 balance. J Allergy Clin Immunol. 2004;113(3):395–400.View ArticlePubMedGoogle Scholar
  43. Jabri B, Kasarda DD, Green PH. Innate and adaptive immunity: the yin and yang of celiac disease. Immunol Rev. 2005;206:219–31.View ArticlePubMedGoogle Scholar
  44. Romagnani S. Th1 and Th2 in human diseases. Clin Immunol Immunopathol. 1996;80(3 Pt 1):225–35.View ArticlePubMedGoogle Scholar
  45. Rengarajan J, Szabo SJ, Glimcher LH. Transcriptional regulation of Th1/Th2 polarization. Immunol Today. 2000;21(10):479–83.View ArticlePubMedGoogle Scholar
  46. Jutras I, Houde M, Currier N, Boulais J, Duclos S, LaBoissiere S, Bonneil E, Kearney P, Thibault P, Paramithiotis E, et al. Modulation of the phagosome proteome by interferon-gamma. Mol Cell Proteomics. 2008;7(4):697–715.View ArticlePubMedGoogle Scholar
  47. Trost M, English L, Lemieux S, Courcelles M, Desjardins M, Thibault P. The phagosomal proteome in interferon-gamma-activated macrophages. Immunity. 2009;30(1):143–54.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2016

Advertisement